series-a
Stage
1
Investors
About
Syntis Bio develops oral therapies targeting the small intestine to treat metabolic health conditions including obesity, diabetes, and rare genetic diseases by leveraging the small intestine’s unique biology.
Explore Syntis Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.